Diuresis

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

Avenacy Announces Launch of Furosemide for Injection in the U.S. Market

Retrieved on: 
Wednesday, March 20, 2024
Hospitals, Pharmaceutical, Health, Cardiology, Furosemide, Cerebral edema, Kidney, Nephrotic syndrome, Route of administration, Entrepreneurship, Diuresis, DCAT, Patient, Boxed warning, Heart, Water, Multimedia, Food, FDA, Liver, Edema, Pharmaceutical industry

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix® for Injection (furosemide) approved by the U.S. Food and Drug Administration.

Key Points: 
  • Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix® for Injection (furosemide) approved by the U.S. Food and Drug Administration.
  • View the full release here: https://www.businesswire.com/news/home/20240320953949/en/
    “The launch of Furosemide for Injection builds on the two launches announced earlier this week and further demonstrates the speed at which we are progressing the business,” said Jeff Yordon, Co-Founder and CEO of Avenacy.
  • Avenacy will begin shipping Furosemide for Injection to wholesale partners next week.
  • The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
Thursday, January 4, 2024
Coma, Urine, Hepatic encephalopathy, Ascites, Kidney, Oliguria, Physician, Benign prostatic hyperplasia, Blood volume, Uric acid, Organic acid, Anuria, Urinary retention, NYHA, Furosemide, Cerebral edema, Hypersensitivity, Diuresis, Thrombosis, Deafness, Glucose, Azotemia, Ototoxicity, Creatinine, Tinnitus, Traction, BUN, Hypoproteinemia, Edema, Growth, Investment, Congestion, Huber loss, Patient, Bruise, Dehydration, CO2, Heart failure, Cirrhosis, Embolism, History, Erythema, Pharmaceutical industry

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.

Boston VNA Nurses and Healthcare Professionals to Cast Votes Authorizing a 14-day Strike on December 11th, Hold Press Conference to Announce Result on December 12th Outside Dorchester Office at 4 p.m.

Retrieved on: 
Monday, December 11, 2023
Legislature, Parkinson's disease, Health, Pet, OASIS, Negotiation, Nursing, Safety, Morale, ALS, MNA, RN, RNS, Patient, Multimedia, Amputation, Retirement, Firearm, Movement, Person-centered therapy, Stroke, Documentation, Data collection, Caregiver, Diuresis, Weakness, Multiple sclerosis, VNA, Ageing, Occupational therapy, Cancer, Social, Medicare, Commonwealth, Therapy, Dignity, Hospital, Greater Boston, Strike, National Nurses United, Workplace, Face, Accident, COVID, Health insurance, Boston, Lymphedema

BOSTON, Dec. 11, 2023 /PRNewswire/ -- In response to an increase in the complexity of care required for patients admitted for care at home, in conjunction with a lack of staff and resources to provide that level of care, the 60 registered nurses (RNs) and healthcare professionals (HCPs) who work for the Visting Nurses Association of Boston/VNA Care (BVNA), will gather throughout the day on Monday to cast a vote to authorize a 14-day strike in an effort to move their administration to provide the staffing and wage enhancements they need to provide the care their patients deserve.

Key Points: 
  • Established in 1886, the Boston VNA — which is owned by Worcester-based VNA Care — is the oldest organized VNA in the country.
  • The medical needs of Boston VNA patients are varied and complex.
  • These professionals, unlike caregivers in institutional settings, such as hospitals and nursing homes, work alone, without the additional staff and resources found in those settings.
  • Founded in 1903, the Massachusetts Nurses Association is the largest union of registered nurses and healthcare professionals in the Commonwealth of Massachusetts.

Boston VNA Nurses and Healthcare Professionals to Cast Votes Authorizing a 14-day Strike on December 11th, Hold Press Conference to Announce Result on December 12th Outside Dorchester Office at 4 p.m.

Retrieved on: 
Friday, December 8, 2023
Legislature, Parkinson's disease, Health, Pet, OASIS, Negotiation, Nursing, Safety, Morale, ALS, MNA, RN, RNS, Patient, Multimedia, Amputation, Retirement, Firearm, Movement, Person-centered therapy, Stroke, Documentation, Data collection, Caregiver, Diuresis, Weakness, Multiple sclerosis, VNA, Ageing, Occupational therapy, Cancer, Social, Medicare, Commonwealth, Therapy, Dignity, Hospital, Greater Boston, Strike, National Nurses United, Workplace, Face, Accident, COVID, Health insurance, Boston, Lymphedema

BOSTON, Dec. 8, 2023 /PRNewswire/ -- In response to an increase in the complexity of care required for patients admitted for care at home, in conjunction with a lack of staff and resources to provide that level of care, the 60 registered nurses (RNs) and healthcare professionals (HCPs) who work for the Boston VNA (BVNA), will gather throughout the day on Monday to cast a vote to authorize a 14-day strike in an effort to move their administration to provide the staffing and wage enhancements they need to provide the care their patients deserve.

Key Points: 
  • Established in 1886, the Boston VNA — which is owned by Worcester-based VNA Care — is the oldest organized VNA in the country.
  • These professionals, unlike caregivers in institutional settings, such as hospitals and nursing homes, work alone, without the additional staff and resources found in those settings.
  • Should the RNs and HCPs vote to authorize the strike, which is expected, the vote does not mean they will strike immediately.
  • Founded in 1903, the Massachusetts Nurses Association is the largest union of registered nurses and healthcare professionals in the Commonwealth of Massachusetts.

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
NYHA, Cirrhosis, FDA, Research, Uric acid, Trial of the century, Deafness, Furosemide, Thrombosis, Erythema, Benign prostatic hyperplasia, Embolism, Internationalized domain name, Government, Hypoproteinemia, History, Kidney, Physician, Cerebral edema, Anuria, Bruise, Edema, Hepatic encephalopathy, Huber loss, Ototoxicity, Chronic kidney disease, Urinary retention, Congestion, Blood volume, Growth, Urine, Dehydration, Shanda, Diuresis, Pharmacy, Tinnitus, Medicaid, Azotemia, BUN, CO2, Oliguria, Organic acid, CKD, Investment, Patient, Creatinine, Heart failure, Hypersensitivity, Glucose, Coma, New York Heart Association Functional Classification, Ascites, Security (finance), Cryptocurrency, Pharmaceutical industry, Rare-earth element, Health insurance, Medical device, Video game, BURLINGTON

BURLINGTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $3.8 million, and cost of product revenues were $1.1 million for the third quarter of 2023.
  • Research and development expenses were $3.4 million for the third quarter of 2023, compared to $3.7 million for the third quarter of 2022.
  • Selling, general and administrative expenses were $14.1 million for the third quarter of 2023, compared to $6.3 million for the third quarter of 2022.
  • As of September 30, 2023, scPharmaceuticals’ total shares outstanding was 35,859,045.
    scPharmaceuticals’ management will host a conference call and webcast to review the Company’s third quarter 2023 results today, Wednesday, November 8, at 4:30 p.m.

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Retrieved on: 
Tuesday, September 19, 2023
Overload, Furosemide, PK, Hypersensitivity, NYHA, Congestion, Embolism, Hypoproteinemia, Organic acid, Heart failure, Hospital, Urine, Creatinine, Cirrhosis, Dehydration, Glucose, Tinnitus, Deafness, Huber loss, Edema, Hepatic encephalopathy, Oliguria, History, Solubility, Type, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Shanda, Investigational New Drug, HIV disease progression rates, Patent, Patient, Physician, Ototoxicity, Urinary retention, Erythema, Azotemia, Ascites, Coma, Type D, Growth, Diagnosis, Blood volume, FDA, Benign prostatic hyperplasia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CKD, Cerebral edema, CO2, Thrombosis, BUN, Food, Kidney disease, Anuria, Pharmaceutical industry

BURLINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the Company has received positive feedback from the U.S. Food and Drug Administration (FDA) on two key long-term growth initiatives.

Key Points: 
  • The Company also announced today feedback from a Type D meeting with the FDA pertaining to the potential expansion of the FUROSCIX label to include treatment of edema due to fluid overload in patients with CKD.
  • In its feedback, the FDA confirmed that no additional clinical studies are needed to expand the indication, provided that the Company demonstrates an adequate PK and pharmacodynamic bridge to the listed drug, furosemide injection, 10 mg/mL.
  • CKD is a progressive disease characterized by worsening renal function over time, resulting in frequent episodes of fluid overload that are treated with loop diuretics.
  • “We are very pleased to have reached alignment with the FDA on the advancement of these two very important long-term growth initiatives for our company,” stated John Tucker, Chief Executive Officer of scPharmaceuticals.

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Medicaid, Hypoproteinemia, Organic acid, Heart failure, Urine, Creatinine, Patient satisfaction, Cirrhosis, Dehydration, Tinnitus, Glucose, Deafness, Huber loss, Edema, Hepatic encephalopathy, Prescription, Research, Part, Oliguria, History, Government, Russell 3000 Index, Trial of the century, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Investment, Patient, Russell, Urinary retention, Cardiology, Azotemia, Ascites, Coma, Blood volume, FDA, Benign prostatic hyperplasia, Thrombosis, IND, Cerebral edema, CO2, BUN, Anuria, Security (finance), Cryptocurrency, Pharmaceutical industry, Health insurance, Medical device, Video game, BURLINGTON

BURLINGTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2023, and provided a business update. 

Key Points: 
  • For the second quarter ended June 30, 2023, scPharmaceuticals reports:
    Obtained national Medicaid coverage of FUROSCIX effective July 1, 2023.
  • Ended the second quarter of 2023 with cash, cash equivalents and short-term investments of $102.9 million.
  • Research and development expenses were $2.9 million for the second quarter of 2023, compared to $5.1 million for the second quarter of 2022.
  • Selling, general and administrative expenses were $12.1 million for the second quarter of 2023, compared to $4.3 million for the second quarter of 2022.

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

Retrieved on: 
Tuesday, August 1, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, US Foods, Hypoproteinemia, Organic acid, Heart failure, Chronic kidney disease, Urine, Creatinine, Cirrhosis, Dehydration, Glucose, Tinnitus, Deafness, Huber loss, Edema, Hepatic encephalopathy, Oliguria, History, Solubility, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Patent, Patient, Physician, Urinary retention, Azotemia, Ascites, Coma, Blood volume, FDA, Benign prostatic hyperplasia, Thrombosis, IND, Cerebral edema, CO2, BUN, Kidney disease, Anuria, Pharmaceutical industry, Medical device

FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure.

Key Points: 
  • FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure.
  • “We are very pleased with the outcome of our recent Type C meeting with the FDA, and believe this paves the way for potential expansion of the FUROSCIX indication to allow for use in NYHA Class IV patients,” stated John Tucker, Chief Executive Officer of scPharmaceuticals.
  • “We estimate that as many as 10% of all heart failure patients are Class IV, and a meaningful percentage of these – as many as 40% - may benefit from FUROSCIX.
  • FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

Retrieved on: 
Friday, June 23, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Hypoproteinemia, Organic acid, Heart failure, Urine, Creatinine, Cirrhosis, Dehydration, Tinnitus, Glucose, Deafness, Huber loss, Edema, FTSE Russell, Hepatic encephalopathy, Oliguria, History, Russell Indexes, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Russell, Patient, Urinary retention, Azotemia, Ascites, Coma, Growth, Blood volume, Benign prostatic hyperplasia, Thrombosis, BUN, Cerebral edema, CO2, Anuria, Pharmaceutical industry, Cryptocurrency

The annual Russell indexes reconstitution captures the 3,000 largest US stocks as of April 28, 2023, ranking them by total market capitalization.

Key Points: 
  • The annual Russell indexes reconstitution captures the 3,000 largest US stocks as of April 28, 2023, ranking them by total market capitalization.
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market capitalization rankings and style attributes.
  • Russell indexes are part of FTSE Russell, a leading global index provider.
  • For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website .